Article
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
Cancer - 1 May 2005
Marin David, Kaeda Jaspal S, Andreasson Catharina, Saunders Sue M, Bua Marco, Olavarria Eduardo, Goldman John M, Apperley Jane F
Abstract excerpt
BACKGROUND: A Phase I/II study was designed to show whether the addition of semisynthetic homoharringtonine (sHHT) would reduce the level of residual disease in patients with Ph-positive chronic myeloid leukemia who appeared to have achieved a suboptimal response to imatinib alone. METHODS: Patients with CML who had achieved >/= 35% Ph-negativity on imatinib were included. All patients had been treated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.